Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director

April 06, 2021

Vitro Biopharma Retains Leading Health Care Executive as Acting  Director of Regulatory Affairs & Director

Vitro Biopharma Retains Leading Health Care Executive as Acting  Director of Regulatory Affairs & Director 

Golden, Colorado-April 3, 2021-Vitro Biopharma, Inc. (formerly Vitro Diagnostics, Inc.)  announced the appointment of Dr. Caroline Mosessian, PhD, DRSc, FACMPE, ACHE as its  acting Director of Regulatory Affairs. Dr. Mosessian has an extensive background in regulatory  science including a PhD, MS and Masters in Healthcare Administration degrees from USC in  LA. In 2016 she was honored with the prestigious Top Ranked US Executive Award awarded to  the top 1% of the millions of active executives in the United States. She is a trusted advisor for  strategic development and operations to a variety of technology firms promoting innovation  excellence to enhance quality of life for patients, caregivers and providers while optimizing  outcomes and overall corporate success. In addition to regulatory expertise, she has extensive  experience in the development, management and licensing of intellectual property, government  and private fund raising, strategic planning and clinical research operations. She is fluent in  several languages that support her international business development skills. She is also actively  involved in local, national and international charitable organizations that emphasize  humanitarian aid. 

She has led numerous clinical studies of medical devices and pharmaceuticals through  regulatory agency approval including the FDA and EMA leading to successful development of  multi-million dollar clinical programs. She presently assists Vitro Biopharma in the guidance,  drafting and submission of its pending IND phase I application to the FDA (Randomized,  Double-blinded, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19). As a result, the FDA has authorized  several expanded access/compassionate use INDs that employ IV infusion of AlloRx Stem  Cells in the treatment of COVID-19 patients.  

https://www.youtube.com/watch?v=V058g5FsUVU 

These results together with several additional clinical studies using MSCs are now providing  substantial clinical evidence of safety and efficacy of stem cell therapy for COVID-19.  Furthermore, since MSC therapy is independent of the genome of the virus, this MSC therapy is likely to be effective in treatment of COVID-19 patients infected with new variants resulting  from viral mutation. 

Dr. Jack Zamora, MD and CEO said, “We are elated to add Dr Mosessian to our regulatory team targeting FDA approval of AlloRx Stem Cells®. She has been instrumental in establishing a  strong working relationship between Vitro Biopharma and the FDA. She will also be a key  driver of the execution of our pending Phase I trial and future INDs targeting additional  indications of AlloRx Stem Cells®.” 

Dr. Mosessian said, "I am inspired by Vitro Biopharma's mission to deliver innovative solutions  and access to regenerative therapies to deliver unmet needs of the vulnerable patients. I feel  fortunate to become part of the team thriving to achieve such an ambitious goal."

John Evans C.F.O. and Chairman of the Board said “ We are pleased to have Caroline join the Board of Directors of the company, she adds such a wide breadth of experience in the regulatory,  clinical and legal areas of board governance. 

ABOUT VITRO BIOPHARMA 

Out of years of research, we developed our patent-pending and proprietary line of umbilical cord  derived stem cells AlloRx Stem Cells® now being used in offshore regenerative medicine  clinical trials. Our stem cells are used in regenerative medicine clinical trials with our partner in  the Cayman Islands www.DVCStem.com. We have a recently approved clinical trial using  our AlloRx Stem Cells® to treat musculoskeletal conditions at The Medical Pavilion of the  Bahamas www.tmp-bahamas.com in Nassau. Our nutraceutical stem cell activation product,  Stemulife™ complements AlloRx Stem Cells® as an adjuvant therapy to optimize therapeutic  outcomes. 

Vitro Biopharma has a proprietary and scalable manufacturing platform to provide stem cell  therapies to critically ill Coronavirus patients and other conditions including multiple sclerosis,  OA, Chrohn’s disease, and numerous medical conditions that are under-treated by the current  standard of care. Our cGMP manufacturing is CLIA, ISO9001, ISO13485 certified and we are  FDA registered. Our stem cells have been shown to be safe and effective in Phase I clinical  trials. 

Forward-Looking Statements 

Statements herein regarding financial performance have not yet been reported to the SEC nor  reviewed by the Company’s auditors. Certain statements contained herein and subsequent  statements made by and on behalf of the Company, whether oral or written may contain  “forward-looking statements”. Such forward-looking statements are identified by words such as  “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation,  statements regarding the Company’s plan of business operations, product research and  development activities, potential contractual arrangements, receipt of working capital,  anticipated revenues, and related expenditures. Factors that could cause actual results to differ  materially include, among others, acceptability of the Company’s products in the market place,  general economic conditions, receipt of additional working capital, the overall state of the  biotechnology industry and other factors set forth in the Company’s filings with the Securities  and Exchange Commission. Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements. Except as  otherwise required by applicable securities statutes or regulations, the Company disclaims any  intent or obligation to update publicly these forward-looking statements, whether as a result of  new information, future events or otherwise. 

CONTACT: 

Dr. Jack Zamora, MD 

Chief Executive Officer 

Vitro Biopharma, Inc.

(303) 999-2130 x 1 

Source: Vitro Biopharma, Inc. www.vitrobiopharma.com



Also in News

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19

April 27, 2021 0 Comments

Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-IIa, randomized, double-blinded, placebo controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19.  Our Investigational New Drug (IND) application  will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy in patients with moderate to severe COVID-19. 

Read More

Vitro Biopharma CEO Jack Zamora
Vitro Biopharma Names World Renowned Physician Entrepreneur as its CEO

December 11, 2020 0 Comments

Golden, Colorado-December 10th, 2020-Vitro Diagnostics, Inc., dba Vitro Biopharma announced the appointment by its Board of Directors of Jack Zamora, MD as its new Chief Executive Officer (“CEO”) and the retention of Dr. James Musick, the current CEO as Chief Science Officer (“CSO”).  Dr. Zamora adds new dimensions to Vitro Biopharma’s senior management team.

Read More

Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells®
Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells®

September 21, 2020 0 Comments

Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, jointly with GIOSTAR – a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science – announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®.

Read More